Cytori Therapeutics, Inc. Announces the Publication of Results from A Pilot Investigator-Initiated Clinical Trial of Cytori Cell Therapy™
January 31, 2019 at 07:00 pm IST
Share
Cytori Therapeutics, Inc. announced the publication of results from a pilot investigator-initiated clinical trial of Cytori Cell Therapy™ for the treatment of refractory perianal fistula in patients with Crohn’s Disease. These findings were published online this month in the journal Gastroenterology1, a publication of the American Gastroenterological Association. The treatment approach involved a single administration of an average dose of 23 M freshly prepared autologous adipose-derived regenerative cells (ADRCs) into the fistulous tract in combination with an autologous adipose micrograft. Cytori Cell Therapy™ was prepared using Cytori’s Celution® 800/CRS System, similar to the product that was recently approved as a Class III medical device in Japan. Crohn’s Disease (CD) is a rare, chronic idiopathic inflammatory bowel disease condition with no cure that is characterized by flares and remission across the entire gastrointestinal tract from the mouth to the anus. Perianal fistulas are a common in CD (26% of patients within 20 years of CD diagnosis) and typically complex (70-80% of perianal fistulas). These fistulas cause pain, depression, a decreased quality of life, and an increased risk of anal epithelia carcinoma. Management of these fistulas has improved over the last 20 years, but even with the latest combined medical and surgical approaches, healing rates have only approached 50%.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.